PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PEPG 11.21.2024

Full Press ReleaseSEC FilingsOur PEPG Tweets

About Gravity Analytica

Recent News

  • 12.16.2024 - PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
  • 11.21.2024 - PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
  • 11.19.2024 - Stifel 2024 Healthcare Conference

Recent Filings

  • 12.16.2024 - EX-99.1 EX-99.1
  • 12.16.2024 - 8-K Current report
  • 11.14.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

BOSTON--(BUSINESS WIRE)--Nov. 21, 2024--PepGen Inc.(Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior Vice President, Clinical Development,Steve Han, MD, PhD, MMSc.

OnNovember 20, 2024,Dr. Hanreceived a non-qualified stock option grant to purchase 95,000 shares of PepGen’s common stock, par value$0.0001per share, with an exercise price of$4.40per share, the closing price of PepGen’s common stock as reported by The Nasdaq Global Select Market onNovember 20, 2024. The inducement grant stock option has a ten-year term and is scheduled to vest over four years, with 25% of the shares vesting on the one-year anniversary of Dr. Han’s employment commencement date and the remainder vesting in equal monthly installments over the following three years, subject to Dr. Han’s continued service toPepGenthrough the applicable vesting dates.

This inducement grant was granted outside of PepGen’s stockholder-approved equity incentive plans pursuant to PepGen’s 2024 Inducement Plan, which was adopted by PepGen’s Board of Directors inAugust 2024. This award was approved by the Compensation Committee of the Board of Directors, which consists entirely of independent directors, as a material inducement to Dr. Han’s entering into employment withPepGenin accordance with Nasdaq Listing Rule 5635(c)(4).

AboutPepGen

PepGenis a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides,PepGenis generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.

For more information, please visitwww.pepgen.com. FollowPepGenonLinkedInandX.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241121499632/en/

InvestorDave Borah, CFASVP, Investor Relations and Corporate Communicationsdborah@pepgen.com

MediaJulia DeutschLyra Strategic AdvisoryJdeutsch@lyraadvisory.com

Source:PepGen Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com